Skip to main navigation

Prime Medicine Logo

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Sec filings
IR Resources

Press Releases

Year

November 12, 2024

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 6, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

October 24, 2024

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

October 15, 2024

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

September 30, 2024

Prime Medicine Unveils Strategically Focused Pipeline

September 30, 2024

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

August 28, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

August 8, 2024

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

May 30, 2024

Prime Medicine to Present at Upcoming Investor Conferences

May 13, 2024

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 25

Print Page

Email Alerts

RSS Feeds

Contact IR

prime_

Site - Footer Bottom

Contact Us
Privacy Policy
Terms of Use

© 2021-2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE and the Prime Medicine logos are trademarks of Prime Medicine, Inc.